Full Press Release Details
YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27thAnnual Global Investment Conference.
A live webcast of the event will be accessible bothhereand on MediWound’s website, under theEvents & Presentationspage of the Investors section.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
For more information visitwww.mediwound.comand follow us onLinkedIn.
MediWound Contacts:
Hani Luxenburg Daniel FerryChief Financial Officer Managing DirectorMediWound Ltd. LifeSci Advisors, LLCir@mediwound.comdaniel@lifesciadvisors.com
Media Contact:Ellie HansonFINN Partners for MediWoundellie.hanson@finnpartners.com+1-929-588-2008